The Motley Fool, founded in 1993 by brothers David and Tom Gardner, is a multimedia financial services company dedicated to empowering individual investors with accessible, actionable advice. Headquartered in Alexandria, Virginia, the company offers a range of products, including stock recommendations, investment research, and personal finance guidance, through its popular website, newsletters, podcasts, and premium subscription services.
4 Medicare Changes Coming Your Way in 2027 It's worth reviewing these before you make any changes to your Medicare coverage for next year.
Forget the COLA. Here's the Social Security Increase You Should Care About. Many seniors focus on the COLA, but there's another increase that will make a bigger difference for their finances.
Stock Market Pattern Echoes the Dot-Com Era and History Points to 1 Move Investors Should Make Now The S&P 500 is trading at valuation levels last seen before the dot-com bubble, with a disconnect between new highs and new lows.
Is Rocket Companies (RKT) Stock a Buy, Sell, or Hold Near Its 52-Week Low? Rocket Companies is becoming a real-estate powerhouse, and its shares seem undervalued.
Here's Where These 4 Nuclear Reactor Stocks Could Be in 5 Years Four nuclear reactor stocks could look very different by 2031, as progress in reactors, revenue growth, and valuations determine shareholder returns.
SpaceX Is Public. Here's What $1,000 in Each of These 5 Space Stocks Could Be Worth by 2030. Space industry experts see this business growing 18% annually over the next five years. Here's what that implies for space stock valuations.
Is Oklo the Next Trillion-Dollar Stock? Could Oklo be the first nuclear company to join the trillion-dollar club?
Prediction: Netflix Stock Is Going to Soar After Oct. 20 Netflix stock looks incredibly cheap heading into its third-quarter earnings report.
4 Vanguard Funds Worth Buying and Holding for the Next 20 Years Tech and AI have dominated the past several years. The next couple of decades could look a lot different.
Better Cryptocurrency to Buy Now With $1,000: Chainlink vs. XRP One of these coins has a fit with its market, and the other hasn't yet found one.
Schwab's Dividend ETF's Worst Year Since 2012 Was a 5.5% Loss. The Cost Showed Up in the Good Years. Its worst calendar year since 2012 was a loss of around 5.5%. What has that steadiness cost in the good years?
Meet the Only AI Stock I'd Buy Over Nvidia in October ASML is thinking years ahead of the AI industry, ensuring it remains an industry leader well into the 2030s.
1 Reason to Buy Carnival Stock (CCL) in October The leading cruise line operator posted all-time-high metrics across the board in Q3.
3 Surging Cryptocurrencies to Buy Now and Hold for 5 Years or More These three coins are positioned to be valuable crypto infrastructure, and they're all gaining traction.
Alphabet Is the Robotaxi Stock to Buy as Waymo Chases 1 Million Rides a Week The robotaxi leader's just halfway to its year-end target. Does the stock need it to get there?
As GLP-1 Drugs Change How People Eat, Drugmakers Collect and Snack Makers Feel the Squeeze The weight-loss drugs are growing in popularity and altering consumer behavior in significant ways.
Costco Stock Is 14% Below Its Record. History Says Buyers Have Usually Been Rewarded. Past dips in the warehouse club's shares have mostly paid off. Does a better September make this one worth buying?
Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore. FDA approval will help, as will insurer adoption of Galleri, but the price that they might be willing to pay for the test is also critical.
History Says This 1 ETF Could Turn $1,000 Into $38,000 in 20 Years. Here's How. If it grows at the rate it's grown over the past three years, your stake could end up worth over $400,000! (But closer to $38,000 is more likely.)
TSMC Reports Oct. 15. It's the Best Early Read on Nvidia's Next Quarter. The AI chip giant won't report for weeks. What can its chipmaker's results show investors first?
Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lens PJP's one-year return beats RSPH's, but RSPH offers broader diversification across 61 healthcare holdings at a lower expense ratio.
Atour's 2026 Outlook: Asset-Light Expansion Scales Hotel Network to 2,175 Locations This under-the-radar hospitality stock boasts a Superscore of 79 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.
Massive News for Chipotle and Starbucks Investors In case you forgot, the current CEO of Starbucks is the former CEO of Chipotle.
Is Coca Cola an Excellent Dividend Stock to Buy Right Now in October? Coca-Cola has a greater market share in away-from-home channels, such as restaurants.
Got $2,000? 2 Natural Gas Pipeline Stocks to Buy Before Winter. Energy Transfer and The Williams Companies are all solid midstream plays.
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.
NICE Stock Analysis: Buy or Sell? A lower price alone is not enough to make a stock a buying opportunity.
Massive Update for AMD Stock Investors The best business in the world could make a poor investment if the price is too high.
I'd Put $500 Into Each of These 5 Dividend Stocks and Throw Away the Statement Because I own stocks like these, I don't worry about my brokerage statements, even though I'm invested in sectors that are currently out of favor.
Consumer Check-In & AI’s Progress Sales are down, guidance has been rough, and with oil and interest rates rising, what is the future for the consumer?
Better Artificial Intelligence Stock: Arm vs. Marvell Technology Arm commands smartphone architecture and is moving into AI CPUs; Marvell dominates data center connectivity with 32.6% net margins.
Can CoreWeave Unseat Amazon Web Services as the Top Cloud Provider? The neocloud company is a rising star, but the hyperscaler has a massive head start.
3 Must-Know COLA Facts Before the Big Announcement Social Security's cost-of-living adjustment (COLA) for 2027 is expected to be announced Oct. 14. What might it mean for you?
Canopy Growth vs. Tilray Brands: Which Healthcare Stock Is a Better Buy in 2026? Canopy pursues a lean U.S.-focused strategy while Tilray has diversified into beverages, but their diverging paths and financial profiles reveal starkly different risk-reward profiles for 2026.
Firefly Aerospace vs. Rocket Lab: Which Industrials Stock Is a Better Buy in 2026? Firefly's hypergrowth masks massive cash burn, while Rocket Lab trades at a premium despite better financial discipline. One valuation gap may matter more than you think.
Where Will Credo Technology Be in 3 Years? This AI networking specialist is growing like a weed, but its future rests on a handful of very big customers. Here's what the next three years could bring.
Redwire vs. Rocket Lab: Which Industrials Stock Is a Better Buy in 2026? Both companies are unprofitable and burning cash, but their paths to scale, and valuations, tell strikingly different stories.
Better Biotechnology ETF: First Trust FBT vs. VanEck BBH VanEck's lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust's $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings.
Could $1,000 Invested in Bitcoin Help You Retire a Millionaire? At one time, Bitcoin had 1,000x upside potential. But is that still the case?
CEO Tom Ward Acquires 172,000 Mach Natural Resources Units for $2.0 Million. Is the Oil Boom a Gusher for the Stock? Ward's purchase through his revocable trust brings his aggregate stake to 28.4 million units, representing a 17.0% ownership interest in the energy partnership.
Coupang vs. MercadoLibre: Which Consumer Stock Is a Better Buy in 2026? Coupang trades at a fraction of MercadoLibre's sales multiple, but the Latin American fintech giant generates far superior margins and cash flow.
